SecBot SecBot
PRESS-RELEASE ·Filed Jul 2, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The data de-risk two Phase 3 strategies in a large, RAS G12D PDAC market (~40% of pancreatic cancer cases) with no approved targeted therapy. Monitor enrollment and interim updates for RASolute 305 and initiation of RASolute 309. The 82% ORR in first-line with mFFX is best-in-class potential, but final Phase 3 OS data are needed for approval. Hold / accumulate on further de-risking.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

RVMD drug pipeline →

daraxonrasib

▲ Bullish Named in this press release
Impact
Phase
Phase 3 (completed with positive results) / pre-NDA
Time to market
NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
Next catalyst
None dated

What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$189.24
T+0 close · Jul 2, 2026 · via day close
Latest settled
+5.61%
T+60 · $199.86
Vs SPY
+2.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 2 $189.24entry
  2. T+1 · 4mo ago +0.40%α −0.48% · $189.99
  3. T+5 · 4mo ago +1.00%α +0.07% · $191.13
  4. T+20 · 4mo ago +1.55%α +1.96% · $192.17
  5. T+60 · 7w ago +5.61%α +2.60% · $199.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines reported positive Phase 1/2 data for zoldonrasib in RAS G12D metastatic pancreatic cancer at ESMO GI 2026. In previously untreated patients, zoldonrasib plus chemotherapy showed an 82% objective response rate (ORR) with mFFX and a 61% ORR with GnP. In previously treated patients, the zoldonrasib plus daraxonrasib doublet achieved a 50% ORR and 9.6-month median progression-free survival in second-line, supporting two Phase 3 trials (RASolute 305 ongoing, RASolute 309 planned).

Key Facts

  • Zoldonrasib plus mFFX in first-line metastatic RAS G12D PDAC: 82% ORR, 96% DCR (n=41).
  • Zoldonrasib plus GnP in first-line: 61% ORR, 90% DCR (n=40).
  • Zoldonrasib plus daraxonrasib in second-line: 50% ORR, 97% DCR, median PFS 9.6 months (n=30).
  • Third-line-plus doublet: 47% ORR, 90% DCR, median OS 10.5 months (n=30).
  • Safety manageable with no Grade 5 TRAEs; discontinuation due to TRAEs low (2-5%).
  • Data support planned Phase 3 RASolute 309 trial of zoldonrasib plus daraxonrasib vs GnP in first-line.
  • RAS G12D is the most prevalent RAS mutation subtype in PDAC (40% of patients), with ~61,000 new US cases/year across all cancers.

Financial Impact

Positive Phase 1/2 data for zoldonrasib-based regimens in RAS G12D pancreatic cancer; supports pivotal Phase 3 trials and expands target market beyond the prior daraxonrasib monotherapy. No revenue or financial guidance provided.

pipeline valueprobability of successaddressable market

Risk Factors

  • Phase 3 trials (RASolute 305, 309) may fail to replicate Phase 1/2 efficacy or show OS benefit.
  • Safety profile with combination regimens may limit the tolerability in broader patient population.
  • Competing RAS-targeted therapies (e.g., from Amgen, Mirati/BMS) could enter the same indication.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3321282

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026